MiR-133a/CD47 axis is a novel prognostic biomarker to promote triple negative breast cancer progression

被引:0
作者
Yan, Honglin [1 ]
Huang, Wenxian [1 ]
Chen, Chuang [2 ]
Zhang, Xiuyun [1 ]
Zhu, Kaimei [3 ]
Yuan, Jingping [1 ]
机构
[1] Wuhan Univ, Dept Pathol, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China
[2] Wuhan Univ, Renmin Hosp, Dept Breast & Thyroid Surg, Wuhan 430060, Hubei, Peoples R China
[3] Wuhan Univ, Dept Gastrointestinal Surg, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China
关键词
miR-133a; CD47; Novel prognostic biomarker; Triple-negative breast cancer; Progression; CD47 INDUCES APOPTOSIS; THERAPEUTIC TARGET; CELL; PHAGOCYTOSIS; EXPRESSION; BLOCKADE; SIRNA; PROLIFERATION; MECHANISMS; ANTIBODIES;
D O I
10.1016/j.prp.2023.154400
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Cluster of differentiation 47 (CD47) acts as an anti-engulfment signal on tumor cells, and its overexpression is correlated with poor prognosis of various malignant tumors. However, the role and mechanism of CD47 in tumor cell proliferation, migration and apoptosis remain unclarified. Emerging evidence indicates that microRNAs (miRNAs) are potential regulators to mediate CD47 generation. In this study, we found that CD47 was upregulated while miR-133a was down-regulated in triple-negative breast cancer (TNBC) in vitro and in vivo. Moreover, we demonstrated for the first time that CD47 was a direct target of miR-133a in TNBC cells, and provided direct evidence of the inverse correlation between miR-133a and CD47 expression in TNBC. Besides, miR-133a functioned as a tumor suppressor to inhibit proliferation and migration, and promote apoptosis of TNBC cells by targeting CD47. Furthermore, overexpression of miR-133a inhibited the tumor growth of TNBC in an in vivo xenograft animal model by targeting CD47. Thus, miR-133a/CD47 axis provides new insight into the mechanism of TNBC progression and could be a promising candidate in the diagnosis and treatment of TNBC.
引用
收藏
页数:13
相关论文
共 45 条
[1]   The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy? [J].
Beizavi, Zahra ;
Gheibihayat, Seyed Mohammad ;
Moghadasian, Hadis ;
Zare, Hossein ;
Yeganeh, Babak Shirazi ;
Askari, Hassan ;
Vakili, Sina ;
Tajbakhsh, Amir ;
Savardashtaki, Amir .
MOLECULAR BIOLOGY REPORTS, 2021, 48 (07) :5707-5722
[2]  
Bergin Alice R T, 2019, F1000Res, V8, DOI [10.12688/f1000research.18888.1, 10.12688/f1000research.18888.1]
[3]   Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy [J].
Chen, Yunching ;
Zhu, Xiaodong ;
Zhang, Xiaoju ;
Liu, Bin ;
Huang, Leaf .
MOLECULAR THERAPY, 2010, 18 (09) :1650-1656
[4]   An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor [J].
Chono, Sumio ;
Li, Shyh-Dar ;
Conwell, Christine C. ;
Huang, Leaf .
JOURNAL OF CONTROLLED RELEASE, 2008, 131 (01) :64-69
[5]   MIR-708 promotes phagocytosis to eradicate T-ALL cells by targeting CD47 [J].
Huang, Wei ;
Wang, Wen-Tao ;
Fang, Ke ;
Chen, Zhen-Hua ;
Sun, Yu-Meng ;
Han, Cai ;
Sun, Lin-Yu ;
Luo, Xue-Qun ;
Chen, Yue-Qin .
MOLECULAR CANCER, 2018, 17
[6]   MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47 [J].
Junker, Andreas ;
Krumbholz, Markus ;
Eisele, Sylvia ;
Mohan, Hema ;
Augstein, Florian ;
Bittner, Robert ;
Lassmann, Hans ;
Wekerle, Hartmut ;
Hohlfeld, Reinhard ;
Meinl, Edgar .
BRAIN, 2009, 132 :3342-3352
[7]   A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer [J].
Kaur, Sukhbir ;
Elkahloun, Abdel G. ;
Singh, Satya P. ;
Chen, Qing-Rong ;
Meerzaman, Daoud M. ;
Song, Timothy ;
Manu, Nidhi ;
Wu, Weiwei ;
Mannan, Poonam ;
Garfield, Susan H. ;
Roberts, David D. .
ONCOTARGET, 2016, 7 (09) :10133-10152
[8]  
Kikuchi Y, 2004, BIOCHEM BIOPH RES CO, V315, P912, DOI 10.1016/j.bbrc.2004.01.128
[9]   Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells [J].
Kim, D. ;
Wang, J. ;
Willingham, S. B. ;
Martin, R. ;
Wernig, G. ;
Weissman, I. L. .
LEUKEMIA, 2012, 26 (12) :2538-2545
[10]  
KNAUF S, 1986, CANCER IMMUNOL IMMUN, V21, P217